Bristol-Myers Squibb Assets & Liabilities Overview 2006-2018 | BMY

Current and historical assets & liabilities overview for Bristol-Myers Squibb (BMY) from 2006 to 2018.
Bristol-Myers Squibb Annual Assets & Liabilities Overview
(Millions of US $)
Bristol-Myers Squibb Quarterly Assets & Liabilities Overview
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $86.637B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.174B 18.29
Pfizer (PFE) United States $261.450B 14.74
Merck (MRK) United States $206.852B 17.92
Novartis AG (NVS) Switzerland $201.155B 17.24
AbbVie (ABBV) United States $130.807B 11.61
Eli Lilly (LLY) United States $120.318B 21.15
Novo Nordisk (NVO) Denmark $110.887B 18.01
Sanofi (SNY) France $109.052B 13.50
AstraZeneca (AZN) United Kingdom $96.706B 12.01
GlaxoSmithKline (GSK) United Kingdom $92.502B 12.43